Although the aforementioned analyses provided a broad picture of the most common genomic alterations occurring in metastatic HR+ HER2- BC specimens, they mostly relied on a small number of paired eBC and mBC samples [3], or they did not report patient therapy [4], thus hindering a full understanding of the interaction between specific treatments and dynamic changes of tumor mutational profiles. The gene discussed is ERBB2; the disease is breast cancer.